Testing treatments for Gram-negative bloodstream infections
Part of Infections clinical trials.
This trial tests different ways to treat infections in the blood caused by Gram-negative bacteria. It looks at whether reducing antibiotics, switching to pills, or managing central lines improves outcomes while keeping you safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be admitted to a hospital that is part of this study.
- You have a blood infection caused by a Gram-negative bacterium (a type of bacteria).
- Doctors are not planning to stop all active treatment for comfort care only.
- You are expected to survive more than 72 hours.
- You have not already joined this platform trial before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether switching from IV to oral antibiotics is just as effective for treating Gram-negative bloodstream infections. If you qualify, you may receive either continued IV antibiotics or switch to pills, with follow-up on your recovery and quality of life.
This trial tests whether people with a specific type of bloodstream infection caused by gram-negative bacteria can safely take antibiotics for only 5 days instead of longer. It may help by reducing antibiotic exposure if your infection source is controlled quickly.
This trial tests the best treatment approach for bloodstream infections caused by Staphylococcus aureus (“S. aureus”). It uses a flexible design to decide which treatment track you fit into, and may help improve recovery while avoiding unnecessary medications.
This trial aims to improve how antibiotics are chosen for patients with resistant bacterial infections in the blood. It uses faster diagnostic tests and expert advice to ensure the most effective treatment.
This study tests different antibiotic combinations for severe infections caused by hard-to-treat Gram-negative bacteria (like Pseudomonas or Acinetobacter). The goal is to find the best treatment for bloodstream infections or pneumonia that started in the hospital.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
Hear when a new Gram-negative Bacteremia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.